Some Investing Thoughts On KemPharm Inc. (NASDAQ: KMPH)

Healthinvest Partners AB has recently announced that it has increased stake in KemPharm Inc. (NASDAQ:KMPH) by 11.94%. After grabbing 0.75 million shares, the institutional investor is now in possession of 80000.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 2.17% having worth around $3.57 million. Moreover, Janney Montgomery Scott LLC increased its share by 160.0 to have a control over 0.48 million shares. And The Retirement Planning Co. of Ne raised its holdings to 14900.0 shares by acquiring 0.3 million shares or 0.88% of the stake.

KemPharm Inc. (KMPH) concluded trading on 01/12/23 at a closing price of $5.49, with 0.36 million shares of worth about $2.0 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 9.15% during that period and on Thursday the price saw a gain of about 10.24%. Currently the company’s common shares owned by public are about 34.49M shares, out of which, 30.28M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 4 analysts are covering the KMPH stock and their offered price forecasts bring an average price target of $19.25. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $28.00 and could fall to a lowest price of $10.00. The stock’s current price level is 71.85% above of average price target set by the analysts, while a rise to estimated low would result in gain of 45.1% for the stock. However, touching the estimated high of $28.00 would mean a gain of 80.39% for the stock.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 19 times over the past 12 months. They bought 27,400 shares in 19 of the transactions. In 0 selling transactions, insiders dumped 0 shares.

Vanguard Total Stock Market Index, HealthInvest Small & Micro Cap Fu, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in KemPharm Inc. Vanguard Total Stock Market Index is currently holding 0.92 million shares of worth totaling $4.38 million. The company recently came buying 20875.0 shares which brought its stake up to 2.67% of the company’s outstanding shares. Vanguard Extended Market Index Fu, after buying 0.43 million shares, have now control over 1.24% of the stake in the company. It holds 0.0 shares of worth $2.03 million.

KemPharm Inc. (NASDAQ: KMPH) started trading at $5.06, above $0.08 from concluding price of the previous day. However, the stock later moved at a day high price of 5.52, or with a gain of 10.24%. Stock saw a price change of 22.54% in past 5 days and over the past one month there was a price change of 20.66%. Year-to-date (YTD), KMPH shares are showing a performance of 19.61% which decreased to -37.83% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.00 but also hit the highest price of $8.97 during that period. The average intraday trading volume for KemPharm Inc. shares is 209.60K. The stock is currently trading 21.43% above its 20-day simple moving average (SMA20), while that difference is up 15.83% for SMA50 and it goes to 7.83% higher than SMA200.

Healthinvest Partners AB acquired 0.75 million shares of KemPharm Inc. having value of about $3.57 million. Data submitted at the U.S SEC by Healthinvest Partners AB revealed that the firm now holds 80000.0 shares in the company valued at close to $439200.0, or have control over 11.94% stake in the company. KemPharm Inc. (NASDAQ: KMPH) currently have 34.49M outstanding shares and institutions hold larger chunk of about 22.80% of that. Holding of mutual funds in the company is about 8.96% while other institutional holders and individual stake holders have control over 9.62% and 10.83% of the stake respectively.

The stock has a current market capitalization of $185.73M and its 3Y-monthly beta is at 2.13. It has posted earnings per share of -$1.02 in the same period. It has Quick Ratio of 10.10 while making debt-to-equity ratio of 0.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KMPH, volatility over the week remained 7.18% while standing at 5.39% over the month.

Analysts are in expectations that KemPharm Inc. (KMPH) stock would likely to be making an EPS of -$0.13 in the current quarter, while forecast for next quarter EPS is -$0.15 and it is -$0.83 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.16 which is -$0.1 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.05 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 34.10% while it is estimated to increase by 38.20% in next year.

Analysts at 4 brokerage firms have issued recommendations for the KemPharm Inc. (KMPH)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.70. Out of those 4 Wall Street analysts, 4 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on November 17, 2022 offering an Overweight rating for the stock and assigned a target price of $20 to it. Coverage by Canaccord Genuity stated KemPharm Inc. (KMPH) stock as a Buy in their note to investors on September 15, 2022, suggesting a price target of $20 for the stock. On January 31, 2022, H.C. Wainwright Upgrade their recommendations, while on March 04, 2021, H.C. Wainwright Downgrade their ratings for the stock with a price target of $12. Stock get a Buy rating from ROTH Capital on January 25, 2021.